Share this video  

BNOS 2022 | How does glioblastoma develop resistance to EFGR inhibitors?

EFGR mutations are present in approximately 60% of glioblastomas but unlike in other cancers, glioblastomas are more resistant to EFGR inhibitors. Igor Vivanco, PhD, King’s College London, London, UK, gives an overview of mechanisms of resistance to EFGR inhibitors in glioblastoma. Inhibition of the tumor suppressor PTEN can lead to resistance, as well as subsequent activation of the PI3K pathway. However, addition of PI3K inhibitors may result in increased toxicity and few can cross the blood-brain barrier. Dr Vivanco suggests finding targets downstream of PI3K to overcome EFGR inhibition. This interview took place at the British Neuro-Oncology Society (BNOS) Annual Meeting 2022.


Dr Vivanco reports has received consulting honoraria from Abbvie and Aadi, as well as research funding from Roche, Genmab, and Basilea.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter